Clinical Trial Update: TCR1020-CD8 T Cells in KRAS-mutated Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of TCR1020-CD8 T cells for KRAS-mutated cancers has been withdrawn, involving metastatic pancreatic cancer and colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• TCR1020-CD8 T cells

Snippet

Sponsor: University of Pennsylvania | Conditions: Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer | Phase 1 | Status: WITHDRAWN